AI biotechs Recursion and Exscientia first held deal talks in 2022
When Recursion Pharmaceuticals and Exscientia announced plans to merge in August, it marked the first major consolidation in the
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
